March 24, 2019 | English | عربي
   Add to Twitter
Boehringer Ingelheim's novel antibody shows potential to transform treatment of rare form of psoriasis
Published in The New England Journal of Medicine, new data show single dose BI 655130* rapidly cleared symptoms of a rare and potentially life-threatening form of pustular psoriasis1

BI 655130 is an investigational, potential first-in-class treatment targeting interleukin-36 receptor (IL-36R)

BI 655130 is being studied in generalised pustular psoriasis as the first of several potential indications, including inflammatory bowel diseases